SK Bioscience “Resign the employee”… Busy incentive preparation ahead of listing

Input 2021.01.28 15:28 | Revision 2021.01.28 15:50

It is known that SK Bioscience, which is about to be listed on the securities market this year, is considering introducing an additional incentive system to prevent the outflow of manpower. This is a measure to prevent employees who received dividends from employee stock ownership from collectively resigning to sell their stocks. It seems that the employees of SK Biopharm, which had been listed last year, felt a sense of crisis when they saw the collective resignation after listing.

According to several SK Bioscience officials on the 28th, SK Bioscience is currently reviewing a plan to pay incentives to long-term employees. The HR team is at the stage of devising the timing and amount of incentive payments, and it has not been announced to employees yet.

SK Bioscience is giving medals and reward holidays to long-term employees for 10 and 20 years on the anniversary of its foundation. The incentive system that the company is currently reviewing has been passed on to provide monetary compensation to employees with short service life.

This system was prepared to prevent employees from leaving after the listing of SK Bioscience. SK Biosciences requested a preliminary examination through NH Investment & Securities, the host company in December of last year, and is expected to be listed on the securities market this year. During the subscription process, executives and employees are allocated employee stock ownership, and immediately after listing, the protection period is at least one year in which the stock cannot be sold. In this case, executives and employees must retire to realize profits by selling stocks.

In fact, SK Biopharm, a subsidiary of SK Group, suffered a massive manpower outflow last year. It is known that since SK Biopharm’s listing in July last year, 70 employees, or 35% of all employees, have signed up.

The group resignation was related to the surge in SK Biopharm’s stock price. Each employee received an average of 11,820 shares, and SK Biopharm shares, which had an offering price of 49,000 won, have once soared to 260,500 won after listing.

In response, an official from SK Bioscience said, “Unlike SK BioPharm, which focuses on R&D, SK Bioscience has already generated steady sales, so there is less concern about leaving employees.” Came out.